Quantitative Concept – Page 19

Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial

5 months ago talkbio0Tagged Keytruda, Malignant neoplasm of lung, Overall Survival, Phase 3 trial, Roche (company), Skyscraper-01, Tecentriq, TIGIT gene, Tiragolumab

Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq

Merck’s Winrevair Demonstrates Significant Mortality Benefit in Pulmonary Arterial Hypertension Patients

5 months ago talkbio0Tagged Benefit, Co., Mortality Vital Statistics, PAH, Pulmonary arterial hypertension, Sotatercept, Winrevair

Winrevair, Pulmonary Arterial Hypertension (PAH), Mortality Benefit, Sotatercept, Merck & Co.

Biohaven’s Taldefgrobep Alfa Shifts Focus to Obesity After Missing Primary Endpoint in Spinal Muscular Atrophy Phase 3 Trial

5 months ago talkbio0Tagged Alfa, Body Composition, Bone and Bones, density, GDF8 protein, human, Inhibitor, lean, Obesity, Phase 3 trial, Spinal Muscular Atrophy

Biohaven, taldefgrobep alfa, spinal muscular atrophy (SMA), obesity, myostatin inhibitor, phase 3 trial, body composition, lean muscle mass, bone density.

AstraZeneca’s Truqap Achieves Phase 3 Success in Prostate Cancer, Paving Way for Label Expansion

5 months ago talkbio0Tagged Antiandrogen therapy, AstraZeneca, CAPItello-281, Hormone Responsive, Malignant neoplasm of prostate, Metastatic to, Phase 3 trial, Progression-Free Survival, PTEN-deficient, Radiographic, rPFS, Truqap

AstraZeneca, Truqap, prostate cancer, Phase 3 trial, CAPItello-281, PTEN-deficient, metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT)

Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study

5 months ago talkbio0Tagged Cardiovascular system, Merck, Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III, Pulmonary arterial hypertension, Winrevair, ZENITH study

Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality

Nabla Bio Revolutionizes AI-Driven Protein Design with $26M Series A Funding and Major Pharmaceutical Collaborations

5 months ago talkbio0Tagged Drug Development, Funding, Generative Protein Design, Multipass Membrane, Pharmaceutical Collaborations, Proteins, Series, Therapeutic Antibodies

Generative Protein Design, AI-Driven Drug Development, Therapeutic Antibodies, Multipass Membrane Proteins, Pharmaceutical Collaborations, Series A Funding